Intellia, holder of rights to UC’s CRISPR technology, to win China patent

Intellia Therapeutics received notice from China's State Intellectual Property Office (SIPO) that it will grant the company a broad patent covering CRISPR/Cas9 single-guide gene-editing methods and compositions. "SIPO's decision further expands our IP portfolio and is further global recognition that Jennifer Doudna, Emmanuelle Charpentier, and their team are the pioneers in the application of CRISPR/Cas9 in all cell types," Nessan Bermingham, Ph.D., Intellia's CEO and president, said in a statement. Read the article.